Breast-specific gamma imaging (BSGI) developer Dilon Diagnostics said that research presented at the recent Chicago International Breast Course showed promising early results from using a low dose of sestamibi in BSGI studies.
Marcela Böhm-Vélez, MD, a breast radiologist from Weinstein Imaging in Pittsburgh, presented preliminary data from a prospective dose reduction study. She said that while image quality at 10 mCi of sestamibi was technically sufficient for clinical imaging, they also discovered that the uptake of sestamibi in breast tissue was not proportional to the dose administered to the patient.
Images conducted using 15 mCi had 90% of the sestamibi concentration in the breast when compared with images conducted at 20 mCi, but that relationship changed as the dose was lowered to 10 or 5 mCi, according to Dilon of Newport News, VA.
Related Reading
Dilon reports positive BSGI research, June 30, 2010
Dilon touts BSGI measurement study, May 3, 2010
BSGI proves best at detecting invasive lobular cancer, February 11, 2009
Breast-specific gamma imaging reveals unseen cancers, December 4, 2008
Dual-head gamma camera increases breast lesion detection, November 28, 2008
Copyright © 2010 AuntMinnie.com
